After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...